Alzheimer's disease drug development pipeline: 2020

• Published in: Alzheimer's & dementia : translational research & clinical interventions Vol. 6; no. 1; pp. e12050 - n/a
• Main Authors: Cummings, Jeffrey, Lee, Garam, Ritter, Aaron, Sabbagh, Marwan, Zhong, Kate
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 2020; John Wiley and Sons Inc; Wiley
• Subjects: Alzheimer's disease; Apoptosis; Biomarkers; Clinical trials; Cognitive enhancement; Common Alzheimer's and Related Dementias Research Ontology (CADRO); Dementia; Drug development; Drugs; NIH; pharmaceutical companies; Pharmaceutical industry; repurposed drugs; Synapses; Terminology; United States > US; biomarkers; drug development; clinical trials; repurposed drugs; NIH; Alzheimer's disease; Common Alzheimer's and Related Dementias Research Ontology (CADRO); pharmaceutical companies

Introduction Alzheimer's disease (AD) is a growing public health concern affecting millions of patients worldwide and costing billions of dollars annually. We review the pipeline of drugs and biologics in clinical trials for the treatment of AD. We use the Common Alzheimer's and Related De...